phenethyl isothiocyanate has been researched along with bortezomib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baggio, R; El Oualid, F; Fasci, D; Hedstrom, L; Lawson, AP; Long, MJC; Qian, Y; Rozhansky, L; Weerapana, E | 1 |
Gartel, AL; Halasi, M; Hay, N; Nogueira, V; Pandit, B; Wang, M | 1 |
2 other study(ies) available for phenethyl isothiocyanate and bortezomib
Article | Year |
---|---|
Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor.
Topics: Carbonates; Deubiquitinating Enzymes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Ubiquitination | 2019 |
Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Administration Schedule; Estradiol; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Isothiocyanates; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Random Allocation; Reactive Oxygen Species; RNA Interference; Transplantation, Heterologous; Treatment Outcome | 2013 |